Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) EBT (2016 - 2025)

Neurocrine Biosciences' EBT history spans 16 years, with the latest figure at $239.4 million for Q4 2025.

  • For Q4 2025, EBT rose 47.23% year-over-year to $239.4 million; the TTM value through Dec 2025 reached $705.4 million, up 45.14%, while the annual FY2025 figure was $705.4 million, 45.14% up from the prior year.
  • EBT reached $239.4 million in Q4 2025 per NBIX's latest filing, down from $291.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $291.8 million in Q3 2025 to a low of -$103.3 million in Q1 2023.
  • Average EBT over 5 years is $91.9 million, with a median of $98.2 million recorded in 2022.
  • Peak YoY movement for EBT: surged 954.35% in 2022, then tumbled 582.71% in 2023.
  • A 5-year view of EBT shows it stood at -$13.8 million in 2021, then soared by 954.35% to $117.9 million in 2022, then skyrocketed by 68.11% to $198.2 million in 2023, then decreased by 17.96% to $162.6 million in 2024, then soared by 47.23% to $239.4 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's EBT are $239.4 million (Q4 2025), $291.8 million (Q3 2025), and $159.5 million (Q2 2025).